Unicycive Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Unicycive Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2020 to 2023.
  • Unicycive Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $45.7M, a 64.4% increase year-over-year.
  • Unicycive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $27.5M.
  • Unicycive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$471K, a 102% decline from 2021.
  • Unicycive Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $22.4M, a 1450% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $27.5M +$28M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$471K -$22.8M -102% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $22.4M +$20.9M +1450% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $1.44M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.